Depletion of gram - positive bacteria within the gut, using an antibiotic called vancomycin, also
increased the efficacy of the therapy, improving the anti-tumor response and overall remission rate in less - responsive mice.
Not exact matches
These risks and uncertainties include: Gilead's ability to achieve its anticipated full year 2018 financial results; Gilead's ability to sustain growth in revenues for its antiviral and other programs; the risk that private and public payers may be reluctant to provide, or continue to provide, coverage or reimbursement for new products, including Vosevi, Yescarta, Epclusa, Harvoni, Genvoya, Odefsey, Descovy, Biktarvy and Vemlidy ®; austerity measures in European countries that may
increase the amount
of discount required on Gilead's products; an
increase in discounts, chargebacks and rebates due to ongoing contracts and future negotiations with commercial and government payers; a larger than anticipated shift in payer mix to more highly discounted payer segments and geographic regions and decreases in treatment duration; availability
of funding for state AIDS Drug Assistance Programs (ADAPs); continued fluctuations in ADAP purchases driven by federal and state grant cycles which may not mirror patient demand and may cause fluctuations in Gilead's earnings; market share and price erosion caused by the introduction
of generic versions
of Viread and Truvada, an uncertain global macroeconomic environment; and potential amendments to the Affordable Care Act or other government action that could have the effect
of lowering prices or reducing the number
of insured patients; the possibility
of unfavorable results from clinical trials involving investigational compounds; Gilead's ability to initiate clinical trials in its currently anticipated timeframes; the levels
of inventory held by wholesalers and retailers which may cause fluctuations in Gilead's earnings; Kite's ability to develop and commercialize cell
therapies utilizing the zinc finger nuclease technology platform and realize the benefits
of the Sangamo partnership; Gilead's ability to submit new drug applications for new product candidates in the timelines currently anticipated; Gilead's ability to receive regulatory approvals in a timely manner or at all, for new and current products, including Biktarvy; Gilead's ability to successfully commercialize its products, including Biktarvy; the risk that physicians and patients may not see advantages
of these products over other
therapies and may therefore be reluctant to prescribe the products; Gilead's ability to successfully develop its hematology / oncology and inflammation / respiratory programs; safety and
efficacy data from clinical studies may not warrant further development
of Gilead's product candidates, including GS - 9620 and Yescarta in combination with Pfizer's utomilumab; Gilead's ability to pay dividends or complete its share repurchase program due to changes in its stock price, corporate or other market conditions; fluctuations in the foreign exchange rate
of the U.S. dollar that may cause an unfavorable foreign currency exchange impact on Gilead's future revenues and pre-tax earnings; and other risks identified from time to time in Gilead's reports filed with the U.S. Securities and Exchange Commission (the SEC).
«Our findings point to the importance
of physicians counseling their patients regarding the potential harms
of smoking interfering with the
efficacy of therapies and for
increased risks
of side effects.»
«We report much higher therapeutic
efficacy in preclinical brain tumor models using the combination
of both
therapies, leading to an
increase in median survival,» Lowenstein says.
Scientists at the Universitat Autònoma de Barcelona (UAB) and the Catalan Institute for Nanoscience and Nanotechnology (ICN2) have developed a nanoencapsulation system with a liposome coating in order to
increase the
efficacy of bacteriophages in oral phage
therapy.
In the sensitive tumor models, the ability
of anti — cytotoxic T lymphocyte — associated protein 4 or anti — programmed cell death 1
therapy to
increase vessel perfusion strongly correlated with its antitumor
efficacy.
Therefore, in order to
increase the
efficacy of therapeutic treatments, combination
therapies are commonly administered.
ERK1 / 2 inhibition
increases antiestrogen treatment
efficacy by interfering with hypoxia - induced downregulation
of ERalpha: a combination
therapy potentially targeting hypoxic and dormant tumor cells
In 2002, the Women's Health Initiative, the first study
of its kind to test the safety and
efficacy of HRT, released results on the
increased risk
of breast cancer and stroke among menopausal women taking combined hormone replacement
therapy.
«Requiring new treatments to show either greater
efficacy or acceptability than an existing standard
therapy would serve as a disincentive to the development
of me - too agents that offer little to patients other than
increased costs,» they write.
SOUND ® has taken its 20 + years
of veterinary experience and developed a
therapy laser with an innovation beyond what currently exists in the market: a built - in laser training assistant specifically designed to
increase efficacy and consistency
of clinical results.
Risk
of relapse among patients diagnosed with major depressive disorder is high (> 50 %
of those recovering from a first episode
of depression, and approximately 80 %
of those with a history
of two or more episodes), 1 and this risk
increases with each successive depressive episode.2 Several clinical trials have demonstrated that mindfulness - based cognitive
therapy (MBCT) significantly reduces relapse risk among patients with three or more prior depressive episodes.3 Yet, MBCT contains multiple therapeutic elements, and the specific
efficacy of the mindfulness training element in MBCT is unknown.
Collaborative
therapy aims to
increase consumer participation and encourage self -
efficacy and self - reliance through psycho - education, with an emphasis on the development
of coping skills and strategies.
«Lisa Dion has created a training program that both
increases the
efficacy of play
therapy and also leads therapists on a journey
of authenticity.»
Summary: (To include comparison groups, outcomes, measures, notable limitations) This study assessed the
efficacy of Trauma - Focused Cognitive - Behavioral
Therapy (TF - CBT) delivered by social worker facilitators in reducing posttraumatic stress, depression, anxiety, and conduct problems and
increasing prosocial behavior in a group
of war - affected, sexually exploited girls.